Natural compounds modulate drug transporter mediated oral cancer treatment
Journal
Biomolecules
Journal Volume
10
Journal Issue
9
Pages
1-11
Date Issued
2020
Author(s)
Abstract
Oral cancer (OC) is a serious health problem. Surgery is the best method to treat the disease but might reduce the quality of life of patients. Photodynamic therapy (PDT) may enhance quality of life but with some limitations. Therefore, the development of a new strategy to facilitate PDT effectiveness has become crucial. ATP-binding cassette G2 (ABCG2) is a membrane protein-associated drug resistance and stemness in cancers. Here, we examined whether ABCG2 plays an important role in regulating the treatment efficacy of PDT and whether ABCG2 inhibition by natural compounds can promote the effect of PDT in OC cells. Several head and neck cancer cells were utilized in this study. OECM1 and SAS cells were selected to investigate the relationship between ABCG2 expression and protoporphyrin IX (PpIX) accumulation. Western blot analysis, flow cytometry analysis, and survival probability were performed to determine PDT efficacy and cellular stemness upon treatment of different dietary compounds, including epigallocatechin gallate (EGCG) and curcumin. In this study, we found that ABCG2 expression varied in OC cells. Hypoglycemic culture for SAS cells enhanced ABCG2 expression as higher ABCG2 expression was associated with lower PpIX accumulation and cellular stemness in OC cells. In contrast, suppression of ABCG2 expression by curcumin and tea polyphenol EGCG led to greater PpIX accumulation and enhanced PDT treatment efficiency in OC cells. In conclusion, ABCG2 plays an important role in regulating the effect of PDT. Change in glucose concentration and treatment with natural compounds modulated ABCG2 expression, resulting in altered PDT efficacy for OC cells. These modulations raise a potential new treatment strategy for early-stage OCs. ? 2020 by the authors. Licensee MDPI, Basel, Switzerland.
Subjects
ATP-binding cassette G2; Oral cancer; Photodynamic therapy; Protoporphyrin IX; Stemness
SDGs
Other Subjects
2 morpholino 8 phenylchromone; aldehyde dehydrogenase; breast cancer resistance protein; curcumin; epidermal growth factor receptor; epigallocatechin gallate; gefitinib; glucose; mitogen activated protein kinase; polyphenol; protein kinase B; transcription factor Nrf2; uvomorulin; ABCG2 protein, human; antineoplastic agent; catechin; curcumin; epigallocatechin gallate; gefitinib; photosensitizing agent; tumor protein; antineoplastic activity; apoptosis; Article; cancer prognosis; cancer stem cell; cell viability; chemoluminescence; clinical outcome; controlled study; down regulation; drug efficacy; FaDu cell line; flow cytometry; gene expression; gene overexpression; head and neck cancer; HSC-3 cell line; human; human cell; IC50; immunohistochemistry; MDA-MB-231 cell line; mouth cancer; MTT assay; OECM-1 cell line; overall survival; photodynamic therapy; polyacrylamide gel electrophoresis; protein expression; quality of life; SAS cell line; Western blotting; cell survival; drug effect; Kaplan Meier method; metabolism; mouth tumor; pathology; photochemotherapy; procedures; tumor cell line; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; Catechin; Cell Line, Tumor; Cell Survival; Curcumin; Gefitinib; Humans; Kaplan-Meier Estimate; Mouth Neoplasms; Neoplasm Proteins; Photochemotherapy; Photosensitizing Agents
Publisher
MDPI AG
Type
journal article